8-K
QHSLab, Inc. (USAQ)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): September 20, 2022
QHSLab,Inc.
(Exact Name of Registrant as Specified in its Charter)
0-19041
(Commission File No.)
| Nevada | 30-1104301 |
|---|---|
| (State<br><br> <br>of<br> Incorporation) | (I.R.S.<br> Employer<br><br> <br>Identification<br> No.) |
| 901<br> Northpoint Parkway Suite 302 West Palm Beach<br><br> <br>FL<br> 33407 | 33407 |
| (Address<br> of Principal Executive Offices) | (ZIP<br> Code) |
Registrant’s telephone number, including area code: (929) 379-6503
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Securitiesregistered pursuant to Section 12(g) of the Act:
| Title of each class | Trading<br><br> <br>Symbol(s) | Name of each exchange<br><br> <br>on which registered |
|---|---|---|
| Common Stock, $0.0001 par value | USAQ | N/A |
Item7.01 Regulation FD Disclosure.
On September 20, 2022, QHSLab, Inc., (the “Company”) issued a press release announcing the launch of a “Long COVID” Digital Health Tool for Primary Care. The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.
We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.
By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website (https://usaqcorp.com), press releases, and various social media channels, including its Twitter account (https://twitter.com/USAQcorp), its LinkedIn account (https://www.linkedin.com/company/usaqcorp) its Facebook account (https://www.facebook.com/USA-Equities-100113722270622), and its Instagram account (https://www.instagram.com/usaqcorp/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.
Item9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits.
The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
| Exhibit<br><br> <br>No. | Description |
|---|---|
| 99.1 | Press Release dated September 20, 2022 QHSLab, Inc. Launches a “Long COVID” Digital Health Tool for Primary Care |
| 104 | Cover<br> Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: September 20, 2022 | |
|---|---|
| QHSLab, Inc. | |
| /s/ Troy Grogan | |
| Name: | Troy<br> Grogan |
| Title: | CEO<br> and Chairman |
Exhibit99.1
QHSLab,Inc. Launches a “Long COVID” Digital Health Tool for Primary Care Physicians
Primarycare physicians now have access to reimbursable digital tools for the routine assessment of post-COVID conditions
| ● | Strengthening QHSLab’s<br> Business Model and Expanding Digital Health Product Portfolio in the Large Primary Care Market |
|---|---|
| ● | Long COVID Digital<br> Health Tool Focused on Primary Care Represents a Compelling and Reimbursable Value Proposition for QHSLab’s Physician Clients |
| ● | 1 in 5 Adults has<br> a New Health Condition that Might be Related to a Previous COVID-19 Infection |
WESTPALM BEACH, FL – (September 20, 2022) (GLOBE NEWSWIRE) – QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point of care technologies, today announced the launch of its proprietary Post-COVID Condition Health Habits digital health tool for screening primary care patients potentially suffering from a “long COVID” or “post-COVID” conditions.
The CDC estimates that 1 in 5 adults over the age of 18 has a health condition that might be related to having had a COVID infection in the past. Currently labeled as a “long COVID” or “post-COVID” condition, defined as having symptoms persisting after or beginning approximately four weeks after first contracting the virus and lasting three or more months after the acute infection, that a patient did not have prior to their COVID-19 infection.
Primary care physicians (PCPs) are usually the first contact for patients suffering from long COVID conditions, and medical researchers are yet to catch up and provide much-needed guidelines for the management of patients complaining of symptoms relating to long COVID conditions. PCPs measure their patient’s health status to form baselines to enable future monitoring of conditions and the effects of treatments. Until now, there have been few easy-to-use, quick, and reimbursable tools to measure a patient’s potential long COVID health and functional status and provide the PCP with clinical decision-making support relating to their patient’s health habits and lifestyle that may improve a patient’s functional status and reduce the risk of future chronic diseases such as heart disease, diabetes, respiratory conditions and mental health, for example.
The latest QHSLab digital health tool has been developed to quickly assess functional status and recovery from COVID-19 and aims to provide PCPs with baseline data relating to measuring long COVID symptoms, including, but not limited to, shortness of breath, pain, fatigue, muscle weakness, memory loss, depression, and anxiety as well as a range of functional limitations, such as changes in lifestyle, work, sports, and social activities.
“This much-needed reimbursable long COVID digital health tool will assist PCPs to initially measure and also track progress over time and has the potential to answer some meaningful clinical questions for long-term research into this new healthcare phenomenon,” said Troy Grogan, President and CEO of QHSLab, Inc.
The Post-COVID-19 Health Habits Assessment supplements the Post-COVID-19 Functional Status (PCFS) scale, designed to assess the functional status of patients previously infected with the SARS-CoV-2 virus, with an assessment of a patient’s current personal health and lifestyle habits, including stress management, diet, exercise, tobacco use, and alcohol consumption.
“Since inception QHSLab has been focused on the vast primary care market, which accounts for 52% of all healthcare utilization in the U.S. PCP’s are looking to companies like QHSLab to assist them in reducing non-clinical administrative burdens and increase practice revenue, enabling them to focus on patient care and satisfaction. Our latest Post-COVID-19 Health Habits Assessment is another way that QHSLab is accomplishing this goal for our medical practice clients,” concluded Grogan.
Medicare and commercial payor reimbursement rates for non-face-to-face services such as QHSLab’s Post-COVID-19 Health Habits Assessment pay PCPs approximately $100 per encounter. QHSLab has launched four core digital health assessments over the past 12 months, covering 100% of patients that see their PCP at any given time. These assessments include mental health evaluation (stress, anxiety, depression, sleep issues, and pain), allergies and asthma, medical nutrition, and post-COVID conditions.
Recent internal data suggests that QHSLab physician clients are generating new revenues in excess of $80-100,000 per year from these additional services, and the Company is just beginning to achieve the validated business model projections of licensing its digital health technology and providing administrative services under contract to its physician client base. Management at QHSLab, Inc. (USAQ) strongly believes that the Company’s current stock price is not reflective of the Company’s true value, its sound fundamental point-of-care and digital healthcare business, near-term prospects, or addressable market opportunities.
For more information, please visit www.qhslab.com.
AboutQHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patients responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving the revenues of their practice.
Forward-LookingStatements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
InvestorRelations Contact:
OliviaGiamanco
QHSLab,Inc.
(929)379-6503
ir@usaqcorp.com
https://twitter.com/USAQcorp